{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:07:50Z","timestamp":1791245270069,"version":"4.1.0"},"reference-count":43,"publisher":"The Endocrine Society","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2004,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The aim of this study was to investigate the effects of the new estro-progestinic containing the antimineralcorticoid progestogen drospirenone (DRSP) in women with polycystic ovary syndrome (PCOS). Fifteen hirsute PCOS patients were treated with 30 \u03bcg ethinyl estradiol plus 3 mg DRSP for 12 cycles. Ultrasonographic pelvic exams, evaluation of hirsutism scores, and hormonal and lipid profile assays were performed at baseline and after three, six, and 12 cycles of treatment. An oral glucose tolerance test and euglycemic hyperinsulinemic clamp were also performed, except at the third cycle. The treatment was well tolerated, and all women attained satisfactory cycle control. Hirsutism significantly improved from the sixth cycle onward. Body weight and fat distribution as well as blood pressure remained stable throughout the treatment. Plasma levels of LH, testosterone, SHBG, and, consequently, the free androgen index significantly fell from the third cycle on. Dehydroepiandrosterone sulfate and 17-hydroxyprogesterone significantly decreased after six cycles. The treatment did not affect glycoinsulinemic homeostasis. A trend toward an increase was seen for total cholesterol, triglycerides, and high- and low-density lipoproteins (HDL and LDL) plasma concentrations, although all parameters remained within the normal range. No modifications in total cholesterol\/HDL and HDL\/LDL ratios were induced by the therapy. The ethinyl estradiol\/DRSP combination seems to be effective in ameliorating clinical and hormonal features of PCOS.<\/jats:p>","DOI":"10.1210\/jc.2003-031158","type":"journal-article","created":{"date-parts":[[2004,6,4]],"date-time":"2004-06-04T21:48:10Z","timestamp":1086385690000},"page":"2817-2823","source":"Crossref","is-referenced-by-count":125,"title":["Drospirenone for the Treatment of Hirsute Women with Polycystic Ovary Syndrome: A Clinical, Endocrinological, Metabolic Pilot Study"],"prefix":"10.1210","volume":"89","author":[{"given":"M.","family":"Guido","sequence":"first","affiliation":[{"name":"Department of Obstetrics and Gynecology, Universita\u0300 Cattolica del Sacro Cuore (M.Gu., D.R., M.Gi., R.S., L.S., R.A., A.L.), 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Romualdi","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Universita\u0300 Cattolica del Sacro Cuore (M.Gu., D.R., M.Gi., R.S., L.S., R.A., A.L.), 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Giuliani","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Universita\u0300 Cattolica del Sacro Cuore (M.Gu., D.R., M.Gi., R.S., L.S., R.A., A.L.), 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Suriano","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Universita\u0300 Cattolica del Sacro Cuore (M.Gu., D.R., M.Gi., R.S., L.S., R.A., A.L.), 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Selvaggi","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Universita\u0300 Cattolica del Sacro Cuore (M.Gu., D.R., M.Gi., R.S., L.S., R.A., A.L.), 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Apa","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Universita\u0300 Cattolica del Sacro Cuore (M.Gu., D.R., M.Gi., R.S., L.S., R.A., A.L.), 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Lanzone","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Universita\u0300 Cattolica del Sacro Cuore (M.Gu., D.R., M.Gi., R.S., L.S., R.A., A.L.), 00168 Rome, Italy"},{"name":"OASI Institute for Researche (A.L.), 94018 Troina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","reference":[{"key":"2020071622335588300_R1","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1056\/NEJM199509283331307","article-title":"Polycystic ovary syndrome.","volume":"333","author":"Franks","year":"1995","journal-title":"N Engl J Med"},{"key":"2020071622335588300_R2","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1111\/j.1749-6632.1993.tb43875.x","article-title":"Results of an open one-year study with Diane 35 in women with polycystic ovary syndrome.","volume":"687","author":"Golland","year":"1993","journal-title":"Ann NY Acad Sci"},{"key":"2020071622335588300_R3","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/0010-7824(90)90002-D","article-title":"Long term treatment with the combination ethinyl-estradiol and cyproterone acetate in polycystic ovary syndrome.","volume":"42","author":"Falsetti","year":"1990","journal-title":"Contraception"},{"issue":"Suppl 11","key":"2020071622335588300_R4","first-page":"981","article-title":"Safety and efficacy of a new oral contraceptive containing drospirenone","volume":"47","author":"Shulman","year":"2002","journal-title":"J Reprod Med"},{"issue":"Suppl 11","key":"2020071622335588300_R5","first-page":"975","article-title":"Evolution of progestins","volume":"47","author":"Thorneycroft","year":"2002","journal-title":"Focus on the novel progestin drospirenone. J Reprod Med"},{"key":"2020071622335588300_R6","author":"Shultz","year":"1996"},{"key":"2020071622335588300_R7","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/S0140-6736(85)92552-8","article-title":"Multifollicular ovaries: clinical and endocrine features and response to gonadotropin releasing hormone.","volume":"2","author":"Adams","year":"1985","journal-title":"Lancet"},{"key":"2020071622335588300_R8","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/S0015-0282(01)01919-7","article-title":"A new ultrasound criterion for the diagnosis of polycystic ovary syndrome: the ovarian stroma\/total area ratio.","volume":"76","author":"Fulghesu","year":"2001","journal-title":"Fertil Steril"},{"key":"2020071622335588300_R9","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1093\/humrep\/14.9.2223","article-title":"Endocrine features of polycystic ovary syndrome in a random population sample of 14\u201316 years old adolescents.","volume":"14","author":"Van Hooff","year":"1999","journal-title":"Hum Reprod"},{"key":"2020071622335588300_R10","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1210\/jcem-57-2-320","article-title":"Genotyping steroid 21-hydroxylase deficiency: hormonal reference data.","volume":"57","author":"New","year":"1983","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071622335588300_R11","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0026-0495(99)90028-8","article-title":"Impact of insulin and body mass index on metabolic and endocrine variables in polycystic ovary syndrome.","volume":"48","author":"Ciampelli","year":"1999","journal-title":"Metabolism"},{"key":"2020071622335588300_R12","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1007\/BF03351044","article-title":"Increased visceral adipose tissue is associated with increased circulating insulin and decreased sex hormone binding globulin levels in massively obese adolescent girls.","volume":"24","author":"De Simone","year":"2001","journal-title":"J Endocrinol Invest"},{"key":"2020071622335588300_R13","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1210\/jcem-21-11-1440","article-title":"Clinical assessment of body hair growth in women.","volume":"21","author":"Ferriman","year":"1961","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071622335588300_R14","first-page":"E214","article-title":"Glucose clamp Technique: a method for quantifying insulin secretion and resistance","volume":"237","author":"De Fronzo","year":"1979","journal-title":"Am J Physiol"},{"key":"2020071622335588300_R15","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1210\/edrv-6-1-45","article-title":"Assessment of insulin sensitivity in vivo.","volume":"6","author":"Bergman","year":"1985","journal-title":"Endocr Rev"},{"key":"2020071622335588300_R16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0010-7824(94)90106-6","article-title":"New progestogens in oral contraception.","volume":"49","author":"Fotherby","year":"1994","journal-title":"Contraception"},{"issue":"Suppl 1A","key":"2020071622335588300_R17","doi-asserted-by":"crossref","first-page":"104s","DOI":"10.1016\/S0002-9343(99)80067-9","article-title":"The androgenicity of progestins","volume":"98","author":"Darney","year":"1995","journal-title":"Am J Med"},{"key":"2020071622335588300_R18","first-page":"577","article-title":"Update on oral contraceptive pills.","volume":"179","author":"Cerel-Suhl","year":"1999","journal-title":"Am J Obstet Gynecol"},{"key":"2020071622335588300_R19","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0010-7824(00)00133-5","article-title":"Drospirenone: pharmacology and pharmacokinetics of a unique progestogen.","volume":"62","author":"Krattenmacher","year":"2000","journal-title":"Contraception"},{"key":"2020071622335588300_R20","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/S0010-7824(96)00195-3","article-title":"The novel progestin drospirenone and its natural counterpart progesterone: biochemical profile and antiandrogenic potential.","volume":"54","author":"Fuhrmann","year":"1996","journal-title":"Contraception"},{"key":"2020071622335588300_R21","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1210\/jcem-38-5-727","article-title":"Dynamic of suppression and recovery of plasma FSH, LH, androstenedione and testosterone in polycystic ovarian disease using an oral contraceptive.","volume":"38","author":"Givens","year":"1974","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071622335588300_R22","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/0010-7824(94)00015-O","article-title":"Drospirenone: a novel progestogen with antimineralocorticoid and antiandrogenic activity: pharmacological characterization in animal models.","volume":"51","author":"Muhn","year":"1995","journal-title":"Contraception"},{"key":"2020071622335588300_R23","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/j.1749-6632.1995.tb31386.x","article-title":"Drospirenone: a novel progestogen with antimineralocorticoid and antiandrogenic activity.","volume":"761","author":"Muhn","year":"1995","journal-title":"Ann NY Acad Sci"},{"key":"2020071622335588300_R24","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1055\/s-2002-36706","article-title":"Regulation of gonadotropin secretion: implications for polycystic ovary syndrome.","volume":"20","author":"McCartney, Eagleson","year":"2002","journal-title":"Semin Reprod Med"},{"key":"2020071622335588300_R25","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1210\/edrv-6-3-400","article-title":"Insulin-like growth factor as intraovarian regulators of granulosa cell growth and function.","volume":"6","author":"Adashi","year":"1985","journal-title":"Endocr Rev"},{"key":"2020071622335588300_R26","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1093\/humrep\/16.1.36","article-title":"Efficacy of the combination ethinyl oestradiol and cyproterone acetate on endocrine, clinical and ultrasonographic profile in polycystic ovarian syndrome.","volume":"16","author":"Falsetti","year":"2001","journal-title":"Hum Reprod"},{"key":"2020071622335588300_R27","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1111\/j.1365-2265.1982.tb01630.x","article-title":"Effect of cyproterone acetate-ethinyl oestradiol treatment on adrenal function in hirsute women.","volume":"17","author":"Chapman","year":"1982","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"Suppl 4","key":"2020071622335588300_R28","first-page":"2","article-title":"The effect of 2 combined oral contraceptives containing either drospirenone or cyproterone acetate on acne and seborrhea","volume":"69","author":"Vloten","year":"2002","journal-title":"Cutis"},{"key":"2020071622335588300_R29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0010-7824(94)90106-6","article-title":"New progestogens in oral contraception.","volume":"49","author":"Fotherby","year":"1994","journal-title":"Contraception"},{"key":"2020071622335588300_R30","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S0306-4530(00)00006-8","article-title":"Increased activity of the hypothalamus-pituitary-adrenal system after treatment with the mineralocorticoid receptor antagonist spironolactone.","volume":"25","author":"Heuser","year":"2000","journal-title":"Psychoneuroendocrinology"},{"key":"2020071622335588300_R31","first-page":"3339","article-title":"The role of mineralocorticoid receptors in hypothalamic-pituitary-adrenal axis regulation in humans.","volume":"83","author":"Young","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071622335588300_R32","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/0039-128X(96)00007-4","article-title":"Effects of estrgens and progestgens on the renin-aldosterone system and blood pressure.","volume":"61","author":"Oelkers","year":"1996","journal-title":"Steroids"},{"key":"2020071622335588300_R33","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1210\/jcem-73-4-837","article-title":"Dihydrospirenone, a new progestogen with antimineralocorticoid activity: effects on ovulation, electrolyte excretion and the renin-aldosterone system in normal women.","volume":"73","author":"Oelkers","year":"1991","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071622335588300_R34","first-page":"1816","article-title":"Effects of new oral contraceptive containing an antimineralocorticoid progestogen, drospirenone, on the renin-aldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolism.","volume":"80","author":"Oelkers","year":"1995","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071622335588300_R35","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0010-7824(00)00083-4","article-title":"An open-label, multicenter study to evaluate Yasmn, a low-dose combination oral contraceptive containing drospirenone, a new progestogen.","volume":"61","author":"Parsey","year":"2000","journal-title":"Contraception"},{"issue":"Suppl 3","key":"2020071622335588300_R36","first-page":"207","article-title":"Oral contraceptives and changes in glucose metabolism: clinical relevance","volume":"7","author":"Skouby","year":"1991","journal-title":"Adv Contraception"},{"key":"2020071622335588300_R37","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/S0002-9378(16)32479-6","article-title":"Carbohydrate metabolism during treatment with estrgen, progestogen and low-dose oral contraceptives.","volume":"142","author":"Spellacy","year":"1982","journal-title":"Am J Obstet Gynecol"},{"key":"2020071622335588300_R38","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1056\/NEJM199011153232003","article-title":"The effects of different formulations of oral contraceptive agents on lipid and carbohydrate metabolism.","volume":"323","author":"Godsland","year":"1990","journal-title":"N Engl J Med"},{"key":"2020071622335588300_R39","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1016\/S0140-6736(97)02358-1","article-title":"Acute myocardial infarction and combined oral contraceptives: results of international multicenter case-control study: WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception.","volume":"349","year":"1997","journal-title":"Lancet"},{"key":"2020071622335588300_R40","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1093\/humupd\/8.3.231","article-title":"Long-term health consequences of PCOS.","volume":"8","author":"Wild","year":"2002","journal-title":"Hum Reprod Update"},{"issue":"Suppl 1","key":"2020071622335588300_R41","first-page":"180","article-title":"Clinical relevance of plasma lipid changes during use of new low-dose oral contraceptives","volume":"7","author":"Gaspard","year":"1991","journal-title":"Adv Contraception"},{"key":"2020071622335588300_R42","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S0002-9149(98)00729-2","article-title":"The new pathophysiology of coronary artery disease.","volume":"82","author":"Castelli","year":"1998","journal-title":"Am J Cardiol"},{"issue":"Suppl 2","key":"2020071622335588300_R43","first-page":"125","article-title":"Cardiovascular risk factors and prevention in women: similarities and differences","volume":"2","author":"Sclavo","year":"2001","journal-title":"Ital Heart J"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/89\/6\/2817\/10744093\/jcem2817.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/89\/6\/2817\/10744093\/jcem2817.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,17]],"date-time":"2020-07-17T10:59:04Z","timestamp":1594983544000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/89\/6\/2817\/2870326"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,6,1]]},"references-count":43,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2004,6,1]]}},"URL":"https:\/\/doi.org\/10.1210\/jc.2003-031158","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,6,1]]}}}